0001104659-26-060234
SEC filingRevenue grew modestly to $19.1M driven by international sales gains despite U.S. price mix headwinds, while gross profit held steady at $12.5M amid higher inventory purchases and obsolescence charges, deepening net losses and cash burn.
Revenue increased 2.9% to $19.1 million in Q1 FY2026 from $18.5 million in the prior-year period, primarily driven by growing international sales, partially offset by price mix headwinds in the U.S. This reflects TELA Bio's ongoing efforts to expand its global footprint with hernia reinforcement devices like OviTex, even as domestic pricing dynamics create counterpressure. Management notes that such volume-driven growth supports scaling, but U.S. market challenges highlight the need for sales force efficiency and GPO contracts to sustain momentum.
Gross profit edged up 6.4% to $12.5 million, delivering a 65.7% gross margin, stable versus the prior period's $12.5 million. The increase in cost of revenue stemmed primarily from higher products purchased to meet demand from elevated unit sales and a greater charge for excess and obsolete inventory. These factors eroded potential margin expansion despite revenue gains, underscoring how sales volume fluctuations directly impact profitability. TELA expects gross margins to continue being affected by royalties, inventory obsolescence risks, and macroeconomic pressures that could delay volume growth and trigger additional charges. The company is exploring lower-cost, higher-margin resorbable polymer-based devices to address these dynamics over time.
Operating income deteriorated 51.6% to -$10.5 million (operating margin -55.2%), signaling persistent operating leverage challenges as R&D and sales investments outpace topline growth. Net income widened 9.0% to -$12.3 million, with diluted EPS loss narrowing 16.0% to -$0.21, benefiting from the smaller revenue base in the comparison period. These results align with TELA's strategy to fund product enhancements, clinical studies like BRAVO II and OPERA, and supply chain resilience amid tariffs on New Zealand imports shared with partner Aroa.
TELA maintains focus on higher-margin innovations and efficient R&D to generate clinical data for expanded indications. Gross profit calculation, subtracting cost of revenue and intangible amortization from revenue, remains a key metric as volume scales. Sales and marketing expenses decreased due to lower commissions offsetting higher training costs, balancing growth investments. While no quantitative guidance is provided, emphasis on cost discipline and product development positions the company to navigate inventory risks and achieve leverage as international traction builds.